Newsletter | May 21, 2020

05.21.20 -- A Wholesaler's View On Biologic Supply During Covid-19

 
Sponsor
Featured Editorial
Industry Insights
Is Your Biologic At Risk For Protein Aggregation? Part 2

The manufacture of sterile injectables is fraught with risk, especially when it comes to protein aggregation in biologics drugs. In part 1 of this article, we discussed causes of protein aggregation and how you can stress test your drug. We now offer steps you can take to help prevent aggregation.

Principles Of Immunogenicity Assessment Using Biacore T200 SPR System

The assessment of unwanted immunogenicity is a key parameter in the development process of biological protein drugs. Usually, ligand binding technologies such as ELISA are used for early immune responses, whereas SPR technology is utilized for the characterization of antibody isotypes, which may be important for the interpretation of the clinical consequences of unwanted immunogenicity.

News Headlines
Solutions